Grit Biotechnology Receives U.S. FDA Clearance of Investigational New Drug Application for GT201, a genetically engineered TIL, following its Chinese IND Approval

SHANGHAI, Aug. 30, 2024 /PRNewswire/ — Grit Biotechnology, a leading clinical-stage cell therapy company focusing on tumor-infiltrating lymphocyte (TIL) therapies, has achieved a major milestone with its genetically engineered TIL product, GT201. Following its investigational new drug…